Evidence map›Paper›PMID 40295031›Full record

Trial reportIn vivo (Athens, Greece)

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102.

Toshifumi Yamaguchi, Motoki Yoshida, Koichi Taira, Shinya Tokunaga, Takeshi Kato, Masato Nakamura, Naotoshi Sugimoto, Soichi Fumita, Masayoshi Yasui, Yasuhiro Miyake and 4 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan; toshifumi.yamaguchi@ompu.ac.jp.
Motoki YoshidaCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Koichi TairaDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Shinya TokunagaDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Takeshi KatoDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Masato NakamuraAizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan.
Naotoshi SugimotoDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Soichi FumitaDepartment of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan.
Masayoshi YasuiDepartment of Surgery, Kaizuka City Hospital, Kaizuka, Japan.
Yasuhiro MiyakeDepartment of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan.
Hisato KawakamiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Higashi-osaka, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Toshio ShimokawaDepartment of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Japan.
Taroh SatohDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe combination of capecitabine and bevacizumab is a standard first-line chemotherapy regimen for vulnerable patients with unresectable colorectal cancer. However, the safety and efficacy of this regimen in Japanese patients have not been sufficiently investigated. PATIENTS AND

methodsThis phase II study included patients aged ≥76 years or those aged 65-75 years who were unsuitable for intensive chemotherapy. Capecitabine at 2000 mg/m

resultsThirty-six patients were enrolled between July 2011 and July 2014, of whom 33 were included in the analysis. The median patient age was 78 years (range=67-86 years). A total of 28 patients had a performance status of 0 or 1, and five of 2. The median progression-free and overall survival were 10.3 (95% confidence interval=9.2-15.4) and 27.9 (95% confidence interval=24.2-50.1) months, respectively. The response and disease control rates were 30.3% and 91.0%, respectively. The major grade 3 or 4 toxicities were hypertension (n=12, 36%) and hand-foot syndrome (n=4, 12%). One patient experienced a grade 4 gastrointestinal perforation.

conclusionThe combination of capecitabine and bevacizumab demonstrated favorable efficacy and tolerability in Japanese patients with metastatic colorectal cancer who were unsuitable for intensive chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsAgedAged, 80 and overBevacizumabCapecitabineFemaleHumansMaleNeoplasm MetastasisTreatment OutcomeBevacizumabCapecitabinecapecitabine plus bevacizumabColorectal cancerelderly

Identifiers

PMID40295031
PMCPMC12041985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.